Literature DB >> 1623646

Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells.

N del Papa1, P L Meroni, W Barcellini, A Sinico, A Radice, A Tincani, D D'Cruz, F Nicoletti, M O Borghi, M A Khamashta.   

Abstract

Twenty-eight out of 62 patients with Wegener's granulomatosis and micropolyarteritis display circulating antiendothelial cell antibodies (AECA) detectable by a cell surface radioimmunoassay. These antibodies do not induce an in vitro endothelial damage either alone or in the presence of fresh complement; however, 50% of IgG-AECA positive sera can be cytotoxic in the presence of human normal peripheral blood mononuclear cells (PBM) at high effector/target ratios. The specificity of the PBM-mediated cytotoxicity is supported by the absence of the phenomenon in AECA negative sera, by the disappearance of the lytic effect after absorption of AECA, and by the finding that cellular-mediated cytotoxicity can be reproduced by purified IgG-AECA positive fractions. On the contrary, polymorphonuclear leukocytes or adherent mononuclear cells are not involved in such a cytotoxic activity. AECA seem to be directed against determinants consitutively expressed on the endothelial surface since the activation of endothelial cells by interleukin-1 beta or interferon-gamma affects neither the antibody binding nor their ability to mediate 51Cr release in the presence of PBM. These findings favor the hypothesis for a possible direct pathogenetic role of circulating AECA in the in vivo vascular damage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623646     DOI: 10.1016/0090-1229(92)90232-d

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  13 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Role of proteinase 3 in activation of endothelium.

Authors:  M E Taekema-Roelvink; C van Kooten; C A Verburgh; M R Daha
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Antiendothelial cell antibodies (AECA) in patients with uveoretinitis.

Authors:  C Edelsten; D P D'Cruz
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 4.  Anti-endothelial cell antibodies and autoimmune diseases.

Authors:  N Del Papa; D Gambini; P L Meroni
Journal:  Clin Rev Allergy       Date:  1994

5.  Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil (PTU)-induced ANCA positive vasculitis are associated with disease activity.

Authors:  F Yu; M-H Zhao; Y-K Zhang; Y Zhang; H-Y Wang
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

6.  Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease.

Authors:  D Aldebert; E Masy; D Reumaux; G Lion; J F Colombel; P Duthilleul
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

7.  Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?

Authors:  B E Ballieux; K T Zondervan; P Kievit; E C Hagen; L A van Es; F J van der Woude; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration.

Authors:  M Blank; Y Tomer; M Stein; J Kopolovic; A Wiik; P L Meroni; G Conforti; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 9.  Mechanisms of endothelial cell injury in vasculitis.

Authors:  A A Pall; C O Savage
Journal:  Springer Semin Immunopathol       Date:  1994

10.  Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch-Schönlein purpura.

Authors:  M Fujieda; N Oishi; K Naruse; M Hashizume; K Nishiya; T Kurashige; K Ito
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.